Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm): A multicenter retrospective study.

View Full Paper
Ask AI
Bookmark
Share

Authors

SMShao MinghuaHZHui ZhangBTBinBin Tan

Discussion

Loading...

Member takes

Overview

Retrospective study shows effective treatment outcomes for unresectable huge HCC, suggesting new therapy options.

Key Points

  • To evaluate the efficacy and safety of Y-90 SIRT combined with Atezo/Bev in patients with unresectable huge HCC.
  • Retrospective multicenter study of 21 patients
  • Treated with Y-90 SIRT plus Atezo/Bev from January 2023 to July 2025
  • Endpoints included ORR, PFS, OS, and safety assessment.
  • Objective response rate (ORR) was 61.9% with 28.6% achieving complete responses (CR)
  • Median OS was not reached; 6- and 12-month PFS rates were 65.1% and 27.1%
  • Grade ≥3 adverse events occurred in 14.3% of patients, but no treatment-related deaths were reported.

Cite This Study

Minghua et al. (2026) studied this question.

synapsesocial.com/papers/6a192da0fab5b468c44168bahttps://doi.org/10.1200/jco.2026.44.16_suppl.4144
View Full Paper
Ask AI
Bookmark
Share